CRIS Curis Inc

Price (delayed)

$0.3466

Market cap

$13.51M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.81

Enterprise value

-$153,985

?
Relative Growth: Rel. Growth: 20
Relative Strength: Rel. Strength: 2
Relative Valuation: Rel. Valuation: 30
Relative Profitability: Rel. Profitability: 31

Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of ...

Highlights
The equity has soared by 133% from the previous quarter
CRIS's debt is down by 49% YoY and by 17% from the previous quarter
The net income has dropped by 179% since the previous quarter but it is up by 50% year-on-year
CRIS's quick ratio has surged by 178% since the previous quarter but it is down by 11% year-on-year
The revenue has declined by 37% year-on-year and by 25% since the previous quarter
The gross profit has contracted by 37% YoY and by 25% from the previous quarter

Key stats

What are the main financial stats of CRIS

CRIS stock price

How has the Curis stock price performed over time
Intraday
-17.89%
1 week
68.42%
1 month
-31.02%
1 year
-80.19%
YTD
-64.89%
QTD
-33.61%

Financial performance

How have Curis's revenue and profit performed over time
Revenue
$7.06M
Gross profit
$7.03M
Operating income
-$7.08M
Net income
-$21.17M
Gross margin
99.6%
Net margin
-299.7%
The net income has dropped by 179% since the previous quarter but it is up by 50% year-on-year
Curis's operating income has surged by 83% YoY but it has decreased by 24% QoQ
CRIS's operating margin has soared by 73% year-on-year but it has dropped by 66% since the previous quarter
The revenue has declined by 37% year-on-year and by 25% since the previous quarter

Price vs fundamentals

How does CRIS's price correlate with its fundamentals

Growth

What is Curis's growth rate over time

Valuation

What is Curis stock price valuation
P/E
N/A
P/B
1.09
P/S
0.95
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.02
Curis's EPS has surged by 87% YoY but it has decreased by 40% QoQ
The equity has soared by 133% from the previous quarter
CRIS's price to sales (P/S) is 91% lower than its 5-year quarterly average of 10.4 and 50% lower than its last 4 quarters average of 1.9
The revenue has declined by 37% year-on-year and by 25% since the previous quarter

Efficiency

How efficient is Curis business performance
Curis's return on sales has increased by 20% YoY
The company's return on assets rose by 18% YoY

Dividends

What is CRIS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRIS.

Financial health

How did Curis financials performed over time
The company's total assets is 75% higher than its total liabilities
CRIS's quick ratio has surged by 178% since the previous quarter but it is down by 11% year-on-year
The current ratio has surged by 127% since the previous quarter but it has declined by 10% year-on-year
CRIS's debt is 89% less than its equity
The equity has soared by 133% from the previous quarter
The debt to equity has soared by 128% YoY but it has shrunk by 63% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.